Skip to content

Neuropace, Inc. NPCE Convertible Preferred Stock Authorized Shares

Convertible Preferred Stock Authorized Shares at other companies

ClearPoint Neuro logo
ClearPoint NeuroCLPT
25M0.0%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
200M0.0%
Biohaven logo
BiohavenBHVN
10M0.0%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s convertible preferred stock authorized shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s convertible preferred stock authorized shares?
Neuropace, Inc. (NPCE) reported convertible preferred stock authorized shares of 10M in Q1 2026.
How has Neuropace, Inc.'s convertible preferred stock authorized shares changed year-over-year?
Neuropace, Inc.'s convertible preferred stock authorized shares decreased by 0.0% year-over-year, from 10M to 10M.
What is the long-term trend for Neuropace, Inc.'s convertible preferred stock authorized shares?
Over 5 years (2020 to 2025), Neuropace, Inc.'s convertible preferred stock authorized shares has grown at a 0.0% compound annual growth rate (CAGR), from 10M to 10M.
What does convertible preferred stock authorized shares mean?
Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.